- Former Senior Vice President and Head of Early Oncology
Development and Clinical Research at Pfizer will lead IDEAYA's
clinical development efforts as Chief Medical Officer
- Over twenty-five years of experience in clinical development
and translational research, including at leading pharmaceutical
companies and major research institutions
SOUTH
SAN FRANCISCO, Calif., Nov. 28,
2022 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(NASDAQ: IDYA), a synthetic lethality focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics, announced that Darrin M. Beaupre, M.D., Ph.D., has joined the
company as its Chief Medical Officer, effective November 21, 2022.
"We are very excited to welcome Dr. Beaupre to IDEAYA. He joins
us as we target to expand our clinical pipeline in the first half
of 2023 to include potentially five clinical trials across four
programs – darovasertib (PKC) in MUM and UM, IDE397 (MAT2A) in
MTAP-deletion tumors, IDE161 (PARG) in HRD tumors and, in
collaboration with GSK, our Pol Theta Helicase Inhibitor
development candidate in HRD tumors. Dr. Beaupre's deep clinical
development and translational research experience will help us
unlock the value of our growing clinical pipeline," said
Yujiro S. Hata, President and Chief
Executive Officer of IDEAYA Biosciences.
"I am pleased to join IDEAYA to help advance the company's
portfolio of potential first-in-class, clinical-stage precision
medicine therapeutics. I share IDEAYA's conviction that synthetic
lethality, an emerging approach within precision medicine oncology,
has considerable promise to deliver new treatments for cancer
patients," said Dr. Darrin M.
Beaupre, M.D., Ph.D., Senior Vice President and Chief
Medical Officer of IDEAYA Biosciences.
Dr. Beaupre's extensive career includes various clinical
development and translational research roles in industry, including
most recently at BioSplice Therapeutics (a subsidiary of Samumed)
as Chief Medical Officer and Head of Research and Development in
Oncology. Dr. Beaupre previously served as Senior Vice President,
Head of Early Oncology Development and Clinical Research at Pfizer,
Inc., where he led cross-disciplinary groups including clinical
development, clinical pharmacology, translational oncology and
clinical operations related study clinicians. There he was
responsible for oversight of IND submissions and early clinical
development across multiple oncology programs. Dr. Beaupre also
served at Pharmacyclics (Abbvie) as Vice President, Head of Early
Development and Immunotherapy, and at Amgen as Medical Director. He
was previously an Assistant Professor at the H. Lee Moffitt Cancer
Center and Research Institute, and also held various earlier
appointments at the University of Miami
and the M.D. Anderson Cancer Center.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates capabilities in
identifying and validating translational biomarkers with drug
discovery to select patient populations most likely to benefit from
its targeted therapies. IDEAYA is applying its early research and
drug discovery capabilities to synthetic lethality – which
represents an emerging class of precision medicine
targets.
Forward-Looking
Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to (i) IDEAYA's
potential clinical trials and (ii) Dr. Beaupre's impact on IDEAYA's
clinical pipeline. IDEAYA undertakes no obligation to update or
revise any forward-looking statements. For a further description of
the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to the business of IDEAYA in general, see
IDEAYA's Quarterly Report on Form 10-Q filed on November 8, 2022 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Paul A. Stone
Senior Vice President and Chief Financial Officer
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-darrin-m-beaupre-md-phd-as-chief-medical-officer-to-lead-clinical-development-of-expanding-clinical-pipeline-301686353.html
SOURCE IDEAYA Biosciences, Inc.